Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function

被引:29
|
作者
Bieber, Michael [1 ]
Schuhmann, Michael K. [1 ]
Volz, Julia [3 ]
Kumar, Gangasani Jagadeesh [4 ,5 ]
Vaidya, Jayathirtha Rao [4 ,5 ]
Nieswandt, Bernhard [3 ]
Pham, Mirko [2 ]
Stoll, Guido [1 ]
Kleinschnitz, Christoph [1 ,6 ]
Kraft, Peter [1 ,7 ]
机构
[1] Univ Hosp Wurzburg, Dept Neurol, Wurzburg, Germany
[2] Univ Hosp Wurzburg, Dept Neuroradiol, Wurzburg, Germany
[3] Univ Wurzburg, DFG Res Ctr Expt Biomed, Rudolf Virchow Ctr, Wurzburg, Germany
[4] Indian Inst Chem Technol, CSIR, Fluro Agro Chem Organ Chem Div 2, Hyderabad, Telangana, India
[5] Indian Inst Chem Technol, CSIR, AcSIR, Hyderabad, Telangana, India
[6] Univ Hosp Essen, Dept Neurol, Essen, Germany
[7] Klinikum Main Spessart, Dept Neurol, Grafen von Rieneck Str 5, D-97816 Lohr, Germany
关键词
blood-brain barrier; brain edema; brain ischemia; cell death; magnetic resonance imaging; neuroprotection; FOCAL CEREBRAL-ISCHEMIA; BRAIN-BARRIER DAMAGE; THROMBO-INFLAMMATION; ANTIPLATELET THERAPY; CILOSTAZOL; NEURODEGENERATION; ACTIVATION; MECHANISMS; ASPIRIN; TARGETS;
D O I
10.1161/STROKEAHA.118.023664
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Acetylsalicylic acid and clopidogrel are the 2 main antithrombotic drugs for secondary prevention in patients with ischemic stroke (IS) without indication for anticoagulation. Because of their limited efficacy and potential side effects, novel antiplatelet agents are urgently needed. Cilostazol, a specific phosphodiesterase (PDE)3 inhibitor, protected from IS in clinical studies comprising mainly Asian populations. Nevertheless, the detailed mechanistic role of PDE-3 inhibitors in IS pathophysiology is hardly understood. In this project, we analyzed the efficacy and pathophysiologic mechanisms of a novel and only recently described PDE-3 inhibitor (substance V) in a mouse model of focal cerebral ischemia. Methods-Focal cerebral ischemia was induced by transient middle cerebral artery occlusion in 6- to 8-week-old male C57Bl/6 wild-type mice receiving substance V or vehicle 1 hour after ischemia induction. Infarct volumes and functional outcomes were assessed between day 1 and day 7, and findings were validated by magnetic resonance imaging. Blood-brain barrier damage, as well as the extent of local inflammatory response and cell death, was determined. Results-Inhibition of PDE-3 by pharmacological blockade with substance V significantly reduced infarct volumes and improved neurological outcome on day 1 and 7 after experimental cerebral ischemia. Reduced blood-brain barrier damage, attenuated brain tissue inflammation, and decreased local cell death could be identified as potential mechanisms. PDE-3 inhibitor treatment did neither increase the number of intracerebral hemorrhages nor affect platelet function. Conclusions-The novel PDE-3 inhibitor substance V protected mice from IS independent from platelet function. Pharmaceutical inactivation of PDE-3 might become a promising therapeutic approach to combat IS via inhibition of thromboinflammatory mechanisms and stabilization of the blood-brain barrier. Visual Overview-An online visual overview is available for this article.
引用
收藏
页码:478 / 486
页数:9
相关论文
共 37 条
  • [1] POOLED SAFETY RESULTS OVER 24 WEEKS FROM THE ENHANCE PROGRAM WITH ENSIFENTRINE, A NOVEL DUAL PHOSPHODIESTERASE (PDE) 3 AND 4 INHIBITOR
    Siler, Thomas M.
    Fogarty, Charles M.
    Rheault, Tara
    Bengtsson, Thomas
    Rickard, Kathleen Ann
    CHEST, 2023, 164 (04) : 4981A - 4983A
  • [2] The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis
    Kraft, Peter
    Schwarz, Tobias
    Goeb, Eva
    Heydenreich, Nadine
    Brede, Marc
    Meuth, Sven G.
    Kleinschnitz, Christoph
    EXPERIMENTAL NEUROLOGY, 2013, 247 : 80 - 90
  • [3] Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke
    Yu Ri Kim
    Ha Neui Kim
    Ki Whan Hong
    Hwa Kyoung Shin
    Byung Tae Choi
    Psychopharmacology, 2016, 233 : 1055 - 1066
  • [4] Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke
    Kim, Yu Ri
    Kim, Ha Neui
    Hong, Ki Whan
    Shin, Hwa Kyoung
    Choi, Byung Tae
    PSYCHOPHARMACOLOGY, 2016, 233 (06) : 1055 - 1066
  • [5] Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in Patients With COPD: Results From Replicate Phase 3 Trials
    Sciurba, F. C.
    Anzueto, A.
    Rheault, T.
    Bengtsson, T.
    Rickard, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [6] Phosphodiesterase 3 (PDE3) attenuates insulin secretion from the human pancreas: A specific PDE3 inhibitor improves insulin secretion in type II diabetes mellitus
    Okada, S
    Ohshima, K
    Mori, M
    ENDOCRINE JOURNAL, 2002, 49 (05) : 581 - 582
  • [7] Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function and Reduces Exacerbation Rate and Risk in Phase 3 Enhance-2 Trial
    Anzueto, A.
    Barjaktarevic, I.
    Rheault, T.
    Bengtsson, T.
    Rickard, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [8] Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, in Moderate and Severe COPD: Symptoms, Quality of Life and Health Status From the Phase 3 Trial Enhance-2
    Rheault, T.
    Bengtsson, T.
    Rickard, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [9] Imer Blocks Phosphorylation of the β3 Integrin, Decreasing Platelet Activation Responses and Protecting Mice From Arterial Thrombosis
    Branchford, Brian R.
    Sather, Susan
    Brodsky, Gary
    White-Adams, Tara C.
    DeRyckere, Deborah
    Neeves, Keith B.
    Wilson, Katina M.
    Lentz, Steven R.
    Graham, Douglas K.
    Di Paola, Jorge A.
    BLOOD, 2011, 118 (21) : 90 - 90
  • [10] The humanized platelet glycoprotein VI Fab inhibitor EMA601 protects from arterial thrombosis and ischaemic stroke in mice
    Navarro, Stefano
    Talucci, Ivan
    Goeb, Vanessa
    Hartmann, Stefanie
    Beck, Sarah
    Orth, Valerie
    Stoll, Guido
    Maric, Hans M.
    Stegner, David
    Nieswandt, Bernhard
    EUROPEAN HEART JOURNAL, 2024, 45 (43) : 4582 - 4597